| Identification | Back Directory | [Name]
Immunoglobulin G,anti-(human carcinoembryonic antigen) (human-mouse monoclonal hMN-14 g-chain), disulfide withhuman-mouse monoclonal hMN-14 k-chain, dimer | [CAS]
219649-07-7 | [Synonyms]
Labetuzumab
Research Grade Labetuzumab(DHC21001)
Immunoglobulin G,anti-(human carcinoembryonic antigen) (human-mouse monoclonal hMN-14 g-chain), disulfide withhuman-mouse monoclonal hMN-14 k-chain, dimer |
| Hazard Information | Back Directory | [Uses]
Treatment of colorectal cancer (humanized monoclonal antibody hMN-14 targeting CEA-
positive cancers). | [Brand name]
CEA-CIDE (Immunomedics). | [in vivo]
Labetuzumab (0.5 mg/rat; i.v.; single) inhibits tumor growth in vivo[1]. | Animal Model: | Female nu/nu mice (6 to 8-week-old; inject TT cells)[1]. | | Dosage: | 0.5 mg/rat | | Administration: | Intravenous injection; single (1 day post-tumor cell injection) | | Result: | Significantly delaied growth of tumor, and led to 64%-70% inhibition of tumor size between days 32 and 60. |
|
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|